Impaired activation of the innate immune response to bacterial challenge in Tourette syndrome

References

• Cheng YH, Zheng Y, He F, Yang JH, Li WB, Wang ML, et al. 2012. Detection of autoantibodies and increased concentrations of interleukins in plasma from patients with Tourette's syndrome. J Mol Neurosci 48:219–224.
   PubMed Web of Science ®Google Scholar
• Elamin I, Edwards MJ, Martino D. 2013. Immune dysfunction in Tourette syndrome. Behav Neurol 27:23–32.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL. 1989. The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006–1011.
   PubMed Web of Science ®Google Scholar
• Hollander M, Wolfe DA, Chicken E. 2013. Nonparametric statistical methods. New York: John Wiley & Sons.
   Google Scholar
• Hanamsagar R, Hanke ML, Kielian T. 2012. Toll-like receptor (TLR) and inflammasome actions in the central nervous system. Trends Immunol 33:333–342.
   PubMed Web of Science ®Google Scholar
• Kitchens RL, Thompson PA. 2005. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 11:225–229.
   PubMedGoogle Scholar
• Krause DL, Muller N. 2012. The relationship between Tourette's syndrome and infections. Open Neurol J 6:124–128.
   PubMedGoogle Scholar
• Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, et al. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 277: 47834–47843.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. 1989. The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566–573.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Kronig H, et al. 2005. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biol Psychiatry 57:667–673.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, et al. 2004. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:4–8.
   PubMed Web of Science ®Google Scholar
• Mallard C. 2012. Innate immune regulation by toll-like receptors in the brain. ISRN Neurology 2012:701950.
   PubMedGoogle Scholar
• Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, et al. 2009. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci 29:9839–9849.
   PubMed Web of Science ®Google Scholar
• Martino D, Dale RC, Gilbert DL, Giovannoni G, Leckman JF. 2009. Immunopathogenic mechanisms in tourette syndrome: a critical review. Mov Disord 24:1267–1279.
   PubMed Web of Science ®Google Scholar
• Matz J, Krause DL, Dehning S, Riedel M, Gruber R, Schwarz MJ, et al. 2012. Altered monocyte activation markers in Tourette's syndrome: a case-control study. BMC Psychiatry 12:29.
   PubMed Web of Science ®Google Scholar
• McGettrick AF, O’Neill LA. 2007. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 139:185–193.
   PubMed Web of Science ®Google Scholar
• Morer A, Chae W, Henegariu O, Bothwell AL, Leckman JF, Kawikova I. 2010. Elevated expression of MCP-1, IL-2 and PTPR-N in basal ganglia of Tourette syndrome cases. Brain Behav Immun 24:1069–1073.
   PubMed Web of Science ®Google Scholar
• Müller N. 2007. Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches. Dialogues Clin Neurosci 9:161–171.
   PubMedGoogle Scholar
• Müller N, Riedel M, Blendinger C, Oberle K, Jacobs E, bele-Horn M. 2004. Mycoplasma pneumoniae infection and Tourette's syndrome. Psychiatry Res 129:119–125.
   PubMed Web of Science ®Google Scholar
• Pollmacher T, Haack M, Schuld A, Kraus T, Hinze-Selch D. 2000. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 34:369–382.
   PubMed Web of Science ®Google Scholar
• Rivest S. 2009. Regulation of innate immune responses in the brain. Nat Rev Immunol 9:429–439.
   PubMed Web of Science ®Google Scholar
• Robertson MM, Eapen V, Cavanna AE. 2009. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 67:475–483.
   PubMed Web of Science ®Google Scholar
• Robertson MM, Stern JS. 1998. Tic disorders: new developments in Tourette syndrome and related disorders. Curr Opin Neurol. 11:373–380.
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, et al. 1998. Pediatric autoimmune neuro psychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 155: 264–271.
   PubMed Web of Science ®Google Scholar
• Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. 2006. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 129:3006–3019.
   PubMed Web of Science ®Google Scholar
• Williams DW, Eugenin EA, Calderon TM, Berman JW. 2012. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 91:401–415.
   PubMed Web of Science ®Google Scholar
• Yang H, Daun JM, Rose JR, Christ WJ, Gusovsky F, Chow JC. 2000. Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccaride antagonists, E5564 and E5531. J Endotoxin Res 6:447–452.
   PubMedGoogle Scholar
• Zhu J, Smith K, Hsieh PN, Mburu YK, Chattopadhyay S, Sen GC, et al. 2010. A high throughput screening for TLR3-IRF3 signaling pathway modulators identifies several antipsychotic drug as TLR inhibitors. J Immunol 184:5768–5776.
   PubMed Web of Science ®Google Scholar